C. Frank Bennett - 07 Jul 2026 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Reporting relationship: EVP, Chief Scientific Officer
Issuer ticker: IONS
Reported as of: 07 Jul 2026
Net transaction value: -$1,744,623
SEC form: 4
Accepted by SEC: 09 Jul 2026, 19:26:31 UTC
Prior SEC filing: 05 Mar 2026
Source filing: View source filing
Reporting owner signature: By: Patrick R. O’Neil, attorney-in-fact For: C. Frank Bennett

Key filing fact

C. Frank Bennett filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 09 Jul 2026.

Key facts

This page summarizes C. Frank Bennett's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Jul 2026, 19:26.

Change

Previous filing in this sequence was filed on 05 Mar 2026.
Current net transaction value: -$1,744,623.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001073387 Primary reporting owner

BENNETT C FRANK

Relationship: EVP, Chief Scientific Officer
Address: 2855 GAZELLE COURT, CARLSBAD
Signature: By: Patrick R. O’Neil, attorney-in-fact For: C. Frank Bennett
Signature date: 09 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IONS transaction

Common Stock

Sale

Transaction value: $462,693
Shares: -5,536
Change %: -6.9%
Price: $83.58
Shares after: 75,018
Date: 07 Jul 2026
Ownership: Direct
Footnotes: F1, F2

IONS transaction

Common Stock

Other

Transaction value
Shares: +15,000
Change %
Price: $0.000000^*
Shares after: 15,000
Date: 07 Jul 2026
Ownership: by Trust
Footnotes: F3

IONS transaction

Common Stock

Sale

Transaction value: $1,281,930
Shares: -15,000
Change %: -100%
Price: $85.46
Shares after: 0
Date: 07 Jul 2026
Ownership: by Trust
Footnotes: F1, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IONS transaction Derivative

Restricted Stock Unit

Other

Transaction value
Shares: -15,000
Change %: -55%
Price: $0.000000^*
Shares after: 12,109
Date: 07 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $0.000000
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 31, 2026.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.070 to $84.065 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

Footnote F3

Represents a transfer of 15,000 shares of common stock from direct ownership to indirect ownership held by the Clarence Frank Bennett TTEE Bennett Living Trust Dated 3/12/2008, of which the reporting person is the co-trustee with spouse.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.015 to $85.730 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

Footnote F5

Restricted Stock Unit vested on January 15, 2026. Upon vesting, the restricted stock unit was paid out in whole shares of Ionis common stock.